Incidence, mechanism and prognostic value of activated AKT in pancreas cancer

被引:217
作者
Schlieman, MG
Fahy, BN
Ramsamooj, R
Beckett, L
Bold, RJ
机构
[1] Univ Calif Davis, Med Ctr, Dept Surg, Sacramento, CA 95817 USA
[2] Univ Calif Davis, Med Ctr, Dept Pathol, Sacramento, CA 95817 USA
[3] Univ Calif Davis, Med Ctr, Dept Epidemiol & Prevent Med, Sacramento, CA 95817 USA
关键词
pancreatic cancer; AKT; HER-2/neu;
D O I
10.1038/sj.bjc.6601396
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
When activated, the serine/threonine kinase AKT mediates an antiapoptotic signal implicated in chemoresistance of various cancers. The mechanism(s) of AKT activation are unknown, though overexpression of HER-2/neu has been implicated in breast cancer, Therefore, we determined the incidence of activated AKT in human pancreatic cancer, whether HER-2/neu is involved in AKT activation, and if AKT activation is associated with biologic behaviour. HER-2/neu expression and AKT activation were examined in seven pancreatic cancer cell lines by Western blotting. The in vitro effect of HER-2/neu inhibition on AKT activation was similarly determined. Finally, 78 pancreatic cancer specimens were examined for AKT activation and HER-2/neu overexpression, and correlated with the clinical prognostic variable of histologic grade. HER-2/neu was overexpressed in two of seven cell lines; these two cell lines demonstrated the highest level of AKT activation. Inhibition of HER-2/neu reduced AKT activation in vitro. AKT was activated in 46 out of 78 (59%) of the pancreatic cancers; HER-2/neu overexpression correlated with AKT activation (P = 0.015). Furthermore, AKT activation was correlated with higher histologic tumour grade (P = 0.047). Thus, it is concluded that AKT is frequently activated in pancreatic cancer; this antiapoptotic signal may be mediated by HER-2/neu overexpression. AKT activation is associated with tumour grade, an important prognostic factor.
引用
收藏
页码:2110 / 2115
页数:6
相关论文
共 40 条
[1]   Pancreatic cancer biology and genetics [J].
Bardeesy, N ;
DePinho, RA .
NATURE REVIEWS CANCER, 2002, 2 (12) :897-909
[2]  
Bondar VM, 2002, MOL CANCER THER, V1, P989
[3]  
Brognard J, 2001, CANCER RES, V61, P3986
[4]   Therapy for pancreatic cancer with a recombinant humanized anti-HER2 antibody (herceptin) [J].
Büchler, P ;
Reber, HA ;
Büchler, MC ;
Roth, MA ;
Büchler, MW ;
Friess, H ;
Isacoff, WH ;
Hines, OJ .
JOURNAL OF GASTROINTESTINAL SURGERY, 2001, 5 (02) :139-146
[5]  
Davies MA, 2002, CLIN CANCER RES, V8, P1904
[6]  
Dhawan P, 2002, CANCER RES, V62, P7335
[7]  
Eskelinen MJ, 1999, EUR J SURG, V165, P292
[8]   AKT inhibition is associated with chemosensitisation in the pancreatic cancer cell line MIA-PaCa-2 [J].
Fahy, BN ;
Schlieman, M ;
Virudachalam, S ;
Bold, RJ .
BRITISH JOURNAL OF CANCER, 2003, 89 (02) :391-397
[9]  
Guerrero S, 2000, CANCER RES, V60, P6750
[10]  
Gupta AK, 2002, CLIN CANCER RES, V8, P885